A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

NCT03540836 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Relacorilant (3x100 mg softgel capsules)
DRUG: Relacorilant (3x100 mg hard-shell capsules)
DRUG: Relacorilant (6x50mg hard-shell capsules)

Sponsor

Corcept Therapeutics